Custom In Vivo Tumor Model Services

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Preclinical Metastatic Tumor Model Services

In the landscape of modern oncology, metastasis remains the primary cause of cancer-related mortality. Alfa Cytology provides high-fidelity Metastatic Tumor Models designed to replicate the complex biological cascade of cancer dissemination. By utilizing Patient-Derived Xenografts (PDX), Syngeneic systems, and innovative "In Vitro-to-In Vivo" pipelines, we empower pharmaceutical partners to evaluate drug efficacy against advanced, resistant, and disseminated malignancies.

The Strategic Necessity of Metastatic Modeling

While primary tumor models are foundational, Metastatic Models are critical for understanding disease progression and drug resistance. The anatomical site of metastasis significantly influences drug penetration, the tumor microenvironment (TME), and therapeutic response.

Our platforms are optimized to support:

Complex Metastatic Cascades: Evaluating efficacy against primary lesions alongside secondary metastatic sites.

Drug Resistance Profiling: Capturing the genomic and histological evolution of metastatic disease.

Imaging & Surgical Integration: Providing a realistic stage for visualizing therapeutic intervention and tumor clearance.

Industry-Leading Capabilities Across Our Portfolio

We integrate cutting-edge methodologies to ensure your drug candidates are tested in environments that mirror the complexity of human cancer:

In vivo tumor engraftment expertise in lung, liver, bone, and brain using PDX and CDX models for metastatic research - Alfa Cytology

Universal Model Construction (PDX & CDX)

We provide flexible engraftment using Patient-Derived Xenografts (PDX) to preserve the genetic heterogeneity of clinical tumors or Cell Line-Derived Xenografts (CDX) for high-throughput consistency. Whether targeting the liver, lung, bone, or brain, our expertise ensures successful metastatic initiation.

Advanced Therapeutic Evaluation (ADCs, Bispecifics & Small Molecules)

Our metastatic models are validated for the evaluation of next-generation biologics:

Antibody-Drug Conjugates (ADCs): Assessing targeted delivery and bystander effects in metastatic lesions.

Bispecific Antibodies: Evaluating T-cell redirection and tumor clearance within immunosuppressive metastatic niches.
Selective Kinase Inhibitors : Identifying effective therapies for refractory metastatic disease, including those demonstrating resistance to standard-of-care agents.

Efficacy evaluation of ADCs and bispecific antibodies in metastatic tumor niches assessing T-cell redirection and bystander effects

Deep learning frameworks for preclinical-to-clinical translation using domain adaptation to predict human drug response outcomes

AI-Driven Clinical Translation

To bridge the gap between bench and clinic, we employ deep learning frameworks to translate preclinical drug responses into clinical patient predictions. By utilizing domain adaptation and systematic data engineering, our models consistently predict human treatment outcomes, significantly reducing late-stage attrition in your pipeline.

Our Services

Validated In Vivo Metastasis Models & Cell Line Biobank

Alfa Cytology provides an extensive, character-verified repository of metastatic models spanning all major oncology indications. Our biobank integrates both Xenograft and Syngeneic platforms, each pre-validated for growth kinetics, organ-specific tropism, and Standard-of-Care (SoC) responsiveness.

Find the optimal model for your drug discovery program below:

Cancer Type	Cell Line	Host Species	Model Type	Metastasis Site
Breast	4T1	Mouse	Syngeneic	Lung (extremely high)
	JIMT-1	Human	Xenograft	Lung / systemic
	MDA-MB-231	Human	Xenograft	Bone / Lung / Brain
	MDA-MB-468	Human	Xenograft	Lung
	MCF-7	Human	Xenograft	Bone
Colon	Colo 205	Human	Xenograft	Ascites / systemic
	HCT 116	Human	Xenograft	Peritoneum / Liver
	HT-29	Human	Xenograft	Liver
	SL4	Mouse	Syngeneic	Liver
	SW620	Human	Xenograft	Lymph node / Liver
Gastric	MFC	Mouse	Syngeneic	Peritoneum / Lung
Gastric	NCI-N87	Human	Xenograft	Liver / Lung
Liver	Hepa1-6	Mouse	Syngeneic	Intrahepatic metastasis
Liver	SMMC-7721	Human	Xenograft	Liver / Lung
Lung	A549	Human	Xenograft	Lung / Brain
	HCC827	Human	Xenograft	Lung
	LLC1	Mouse	Syngeneic	Lung
	NCI-H1975	Human	Xenograft	Brain / systemic
	PC-9	Human	Xenograft	Brain
Melanoma	A375	Human	Xenograft	Lung / systemic
	B16-F10	Mouse	Syngeneic	Lung
	YUMM1.7	Mouse	Syngeneic	Lung / lymph
Pancreas	AsPC-1	Human	Xenograft	Peritoneum / Liver
Pancreas	Pan02	Mouse	Syngeneic	Liver / peritoneum
Prostate	LNCaP	Human	Xenograft	Lymph nodes
	PC-3	Human	Xenograft	Bone (osteolytic)
	RM-1	Mouse	Syngeneic	Lung / Bone

Why Choose Alfa Cytology for Metastatic Research?

Full-Spectrum Oncology Expertise

Validated platforms for all common and rare metastatic indications.

High-Fidelity Translation

AI-driven prediction and PDX-organoid integration ensure data relevance to human clinical reality.

Regulatory Excellence

Comprehensive data packages designed to meet international regulatory requirements for drug approval submissions.

Integrated Analytical Suite

Seamless pipeline from surgical model initiation to biomarker validation and immune profiling.

Contact Us for Tailored Metastatic Solutions

Alfa Cytology's metastatic model services provide a versatile and clinically relevant platform to accelerate your drug discovery pipeline. Whether your focus is on targeted inhibitors or complex biologics, we partner with you to generate the data needed to change the course of cancer treatment. Contact us today to discuss how our full-spectrum metastatic solutions can be tailored to meet your research milestones.

For research use only. Not intended for any clinical use.